Mesoblast Limited (ASX:MSB) To Present At Goldman Sachs (NYSE:GS) 32nd Annual Global Healthcare Conference

Global regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that its Chief Executive, Silviu Itescu, will present at the Goldman Sachs (NYSE:GS) 32nd Annual Global Healthcare Conference in the United States. Mesoblast joins Resmed and Ramsay Healthcare as the only Australian companies participating in the global investor forum.

Professor Itescu is due to speak at the conference in Los Angeles on Wednesday 8 June at 8:40 a.m. US PT (Thursday, 9 June at 1:40 a.m. in Melbourne).

To access a live audio webcast of the presentation you may use the link: http://cc.talkpoint.com/gold006/060711a_lr/?entity=67_IKXHJB0' target=_blank>http://cc.talkpoint.com/gold006/060711a_lr/?entity=67_IKXHJB0' target=_blank>http://cc.talkpoint.com/gold006/060711a_lr/?entity=67_IKXHJB0.

An archived version of the webcast will be available until 15 June 2011.

About Mesoblast Limited

Mesoblast Limited (ASX:MSB) (OTC ADR: MBLTY) is the world's leading developer of innovative biological products for the broad field of regenerative medicine.

Mesoblast's commercial strategy is based on its unique proprietary adult mesenchymal precursor cells.

The company's lead products will target cardiovascular conditions, diabetes, inflammatory conditions of lungs and joints, eye diseases, bone marrow cancers, bone fractures, cartilage degeneration and musculoskeletal conditions.

Mesoblast and global biopharmaceutical company Cephalon Inc. have established a strategic alliance to commercialize adult stem cell products for degenerative conditions of the cardiovascular and central nervous systems. The alliance also extends to products for augmenting bone marrow transplantation in cancer patients.


Related Companies

Mesoblast Limited
      

Goldman Sachs Group